ABCELLERA BIOLOGICS - Asset Resilience Ratio

Latest as of December 2025: 29.87%

ABCELLERA BIOLOGICS (8QQ) has an Asset Resilience Ratio of 29.87% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ABCELLERA BIOLOGICS total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€405.31 Million

≈ $473.85 Million USD Cash + Short-term Investments

Total Assets

€1.36 Billion

≈ $1.59 Billion USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how ABCELLERA BIOLOGICS's Asset Resilience Ratio has changed over time. See what is ABCELLERA BIOLOGICS's book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ABCELLERA BIOLOGICS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ABCELLERA BIOLOGICS stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€405.31 Million	29.87%
Total Liquid Assets	€405.31 Million	29.87%

Asset Resilience Insights

Very High Liquidity: ABCELLERA BIOLOGICS maintains exceptional liquid asset reserves at 29.87% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

ABCELLERA BIOLOGICS Industry Peers by Asset Resilience Ratio

Compare ABCELLERA BIOLOGICS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for ABCELLERA BIOLOGICS (2021–2025)

The table below shows the annual Asset Resilience Ratio data for ABCELLERA BIOLOGICS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	29.87%	€405.31 Million ≈ $473.85 Million	€1.36 Billion ≈ $1.59 Billion	-4.62pp
2024-12-31	34.49%	€469.29 Million ≈ $548.65 Million	€1.36 Billion ≈ $1.59 Billion	-7.66pp
2023-12-31	42.15%	€627.26 Million ≈ $733.34 Million	€1.49 Billion ≈ $1.74 Billion	+9.71pp
2022-12-31	32.45%	€499.95 Million ≈ $584.49 Million	€1.54 Billion ≈ $1.80 Billion	+13.73pp
2021-12-31	18.72%	€246.84 Million ≈ $288.58 Million	€1.32 Billion ≈ $1.54 Billion	--

pp = percentage points

About ABCELLERA BIOLOGICS

F:8QQ Germany Biotechnology

Market Cap

$1.15 Billion

€983.76 Million EUR

Market Cap Rank

#9578 Global

#1165 in Germany

Share Price

€3.25

Change (1 day)

-2.26%

52-Week Range

€1.75 - €5.24

All Time High

€44.98